Soluble Guanylate Cyclase. Allosteric Activation and Redox Regulation.

Nitric Oxide

Volumn , Issue , 2010, Pages 301-326

  Hobbs, Adrian J ^a   Stasch, Johannes Peter ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049287515     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373866-0.00009-5     Document Type: Chapter

References (194)

1. Ahluwalia A., Foster P., Scotland R.S., McLean P.G., Mathur A., Perretti M., Moncada S., Hobbs A.J. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc. Natl Acad. Sci. U S A 2004, 101:1386-1391.
2. Ahluwalia A., MacAllister R.J., Hobbs A.J. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res. Cardiol. 2004, 99:83-89.
3. Amirmansour C., Vallance P., Bogle R.G. Tyrosine nitration in blood vessels occurs with increasing nitric oxide concentration. Br. J. Pharmacol. 1999, 127:788-794.
4. Ashman D.F., Lipton R., Melicow M.M., Price T.D. Isolation of adenosine 3′, 5′-monophosphate and guanosine 3′, 5′-monophosphate from rat urine. Biochem. Biophys. Res. Commun. 1963, 11:330-334.
5. Bainbridge S.A., Farley A.E., McLaughlin B.E., Graham C.H., Marks G.S., Nakatsu K., Brien J.F., Smith G.N. Carbon monoxide decreases perfusion pressure in isolated human placenta. Placenta 2002, 23:563-569.
6. Baracat J.S., Teixeira C.E., Okuyama C.E., Priviero F.B., Faro R., Antunes E., De N.G. Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur. J. Pharmacol. 2003, 477:163-169.
7. Becker E.M., Alonso-Alija C., Apeler H., Gerzer R., Minuth T., Pleibeta U., Schmidt P., Schramm M., Schroder H., Schroeder W., Steinke W., Straub A., Stasch J.P. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol 2001, 1:13.
8. Becker E.M., Schmidt P., Schramm M., Schroder H., Walter U., Hoenicka M., Gerzer R., Stasch J.P. The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. J. Cardiovasc. Pharmacol. 2000, 35:390-397.
9. Bellamy T.C., Wood J., Garthwaite J. On the activation of soluble guanylyl cyclase by nitric oxide. Proc. Natl Acad. Sci. U S A 2002, 99:507-510.
10. Berkan O., Bagcivan I., Kaya T., Yildirim K., Yildirim S., Dogan K. Investigation of the vasorelaxant effects of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft. Can. J. Physiol Pharmacol. 2007, 85:521-526.
11. Bischoff E., Stasch J.P. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation 2004, 110:e320-e321.
12. Bischoff E., Schramm M., Straub A., Feurer A., Stasch J.P. BAY 41-2272: a stimulator of soluble guanylyl cyclase induces nitric oxide-dependent penile erection in vivo. Urology 2003, 61:464-467.
13. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., Lapp H., Stasch J.P., Burnett J.C. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007, 49:1128-1133.
14. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., Tsuruda T., Harty G.J., Lapp H., Stasch J.P., Burnett J.C. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 2003, 107:686-689.
15. Boon E.M., Marletta M.A. Ligand discrimination in soluble guanylate cyclase and the H-NOX family of heme sensor proteins. Curr. Opin. Chem. Biol. 2005, 9:441-446.
16. Braughler J.M. Soluble guanylate cyclase activation by nitric oxide and its reversal. Involvement of sulfhydryl group oxidation and reduction. Biochem. Pharmacol. 1983, 32:811-818.
17. Brown G.C. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett. 1995, 369:136-139.
18. Brunton T.L. Use of nitrite of amyl in angina pectoris. Lancet 1867, 1857II:561-564.
19. Budworth J., Meillerais S., Charles I., Powell K. Tissue distribution of the human soluble guanylate cyclases. Biochem. Biophys. Res. Commun. 1999, 263:696-701.
20. Burnett J.C. Vasopeptidase inhibition: a new concept in blood pressure management. J. Hypertens. Suppl 1999, 17:S37-S43.
21. Burrell L.M., Farina N.K., Balding L.C., Johnston C.I. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension 2000, 36:1105-1111.
22. Burstyn J.N., Yu A.E., Dierks E.A., Hawkins B.K., Dawson J.H. Studies of the heme coordination and ligand binding properties of soluble guanylyl cyclase (sGC): characterization of Fe(II)sGC and Fe(II)sGC(CO) by electronic absorption and magnetic circular dichroism spectroscopies and failure of CO to activate the enzyme. Biochemistry 1995, 34:5896-5903.
23. Cary S.P., Marletta M.A. The case of CO signaling: why the jury is still out. J. Clin. Invest. 2001, 107:1071-1073.
24. Cary S.P., Winger J.A., Derbyshire E.R., Marletta M.A. Nitric oxide signaling: no longer simply on or off. Trends Biochem. Sci. 2006, 31:231-239.
25. Cau S.B., Dias-Junior C.A., Montenegro M.F., de Nucci G., Antunes E., Tanus-Santos J.E. Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. Eur. J. Pharmacol. 2008, 581:132-137.
26. Cellek S., Rees R.W., Kalsi J. A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin. Investig. Drugs 2002, 11:1563-1573.
27. Cetin A., Kaya T., Demirkoprulu N., Karadas B., Duran B., Cetin M. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits the spontaneous contractions of isolated pregnant rat myometrium. J. Pharmacol. Sci. 2004, 94:19-24.
28. Che Y., Ellis A., Li C.G. Enhanced responsiveness to nitric oxide, nitroxyl anions, and nitrergic transmitter by 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole in the rat anococcygeus muscle. Nitric Oxide 2005, 13:118-124.
29. Chen Z., Zhang J., Stamler J.S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl Acad. Sci. U S A 2002, 99:8306-8311.
30. Chien W.L., Liang K.C., Teng C.M., Kuo S.C., Lee F.Y., Fu W.M. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol. Pharmacol. 2003, 63:1322-1328.
31. Chien Y.H., Bau D.T., Jan K.Y. Nitric oxide inhibits DNA-adduct excision in nucleotide excision repair. Free Radic. Biol. Med. 2004, 36:1011-1017.
32. Chirkov Y.Y., Horowitz J.D. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol. Ther 2007, 116:287-305.
33. Chun Y.S., Yeo E.J., Choi E., Teng C.M., Bae J.M., Kim M.S., Park J.W. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 2001, 61:947-954.
34. Corti R., Burnett J.C., Rouleau J.L., Ruschitzka F., Luscher T.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?. Circulation 2001, 104:1856-1862.
35. Craven P.A., DeRubertis F.R. Effects of thiol inhibitors on hepatic guanylate cylase activity. Biochim. Biophys. Acta 1978, 524:231-244.
36. Denninger J.W., Schelvis J.P., Brandish P.E., Zhao Y., Babcock G.T., Marletta M.A. Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. Biochemistry 2000, 39:4191-4198.
37. Deruelle P., Balasubramaniam V., Kunig A.M., Seedorf G.J., Markham N.E., Abman S.H. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol. Neonate 2006, 90:135-144.
38. Deruelle P., Grover T.R., Storme L., Abman S.H. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L727-L733.
39. Dierks E.A., Burstyn J.N. Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble guanylyl cyclase. Biochem. Pharmacol. 1996, 51:1593-1600.
40. Dumitrascu R., Weissmann N., Ghofrani H.A., Dony E., Beuerlein K., Schmidt H., Stasch J.P., Gnoth M.J., Seeger W., Grimminger F., Schermuly R.T. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006, 113:286-295.
41. Evgenov O.V., Ichinose F., Evgenov N.V., Gnoth M.J., Falkowski G.E., Chang Y., Bloch K.D., Zapol W.M. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004, 110:2253-2259.
42. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H.H., Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov. 2006, 5:755-768.
43. Evgenov O.V., Kohane D.S., Bloch K.D., Stasch J.P., Volpato G.P., Bellas E., Evgenov N.V., Buys E.S., Gnoth M.J., Graveline A.R., Liu R., Hess D.R., Langer R., Zapol W.M. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am. J. Respir. Crit. Care Med. 2007, 176:1138-1145.
44. Ferrero R., Rodriguez-Pascual F., Miras-Portugal M.T., Torres M. Nitric oxide-sensitive guanylyl cyclase activity inhibition through cyclic GMP-dependent dephosphorylation. J. Neurochem. 2000, 75:2029-2039.
45. Filippov G., Bloch D.B., Bloch K.D. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J. Clin. Invest. 1997, 100:942-948.
46. Foerster J., Harteneck C., Malkewitz J., Schultz G., Koesling D. A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits. Eur. J. Biochem. 1996, 240:380-386.
47. Freitas C.F., Morganti R.P., nnichino-Bizzacchi J.M., De N.G., Antunes E. Effect of BAY 41-2272 in the pulmonary hypertension induced by heparin-protamine complex in anaesthetized dogs. Clin. Exp. Pharmacol. Physiol. 2007, 34:10-14.
48. Frey R., Mück W., Unger S., Artmeier-Brandt U., Weimann G., Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J. Clin. Pharmacol. 2008, 48:926-934.
49. Frey R., Mück W., Unger S., Artmeier-Brandt U., Weimann G., Wensing G. Pharmacokinetics, pharmacodynamics, tolerability and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J. Clin. Pharmacol. 2008, 48:1400-1410.
50. Friebe A., Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol. 1998, 53:123-127.
51. Friebe A., Russwurm M., Mergia E., Koesling D. A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site?. Biochemistry 1999, 38:15253-15257.
52. Friebe A., Schultz G., Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 1996, 15:6863-6868.
53. Friebe A., Wedel B., Harteneck C., Foerster J., Schultz G., Koesling D. Functions of conserved cysteines of soluble guanylyl cyclase. Biochemistry 1997, 36:1194-1198.
54. Furchgott R.F. Studies on the relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is organic nitrite and the endothelium-derived relaxing factor is nitric oxide. Mechanisms of Vasodilatation 1988, 31-36. Raven Press, New York. P.M. Vanhoutte (Ed.).
55. Galle J., Zabel U., Hubner U., Hatzelmann A., Wagner B., Wanner C., Schmidt H.H. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol. 1999, 127:195-203.
56. Garthwaite G., Goodwin D.A., Neale S., Riddall D., Garthwaite J. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition. Mol. Pharmacol. 2002, 61:97-104.
57. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 1995, 48:184-188.
58. Ghofrani H.A., Weimann G., Frey R., Voswinckel R., Thamm M., Bolkow D., Weissmann N., Muck W., Unger S., Wensing G., Schermuly R.T., Grimminger F. BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacol 2007, 7(Suppl. 1):S8.
59. Gladwin M.T. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J. Clin. Invest 2006, 116:2330-2332.
60. Gonzalez-Luis G., Cogolludo A., Moreno L., Lodi F., Tamargo J., Perez-Vizcaino F., Villamor E. Relaxant effects of the soluble guanylate cyclase activator and NO sensitizer YC-1 in piglet pulmonary arteries. Biol. Neonate 2006, 90:66-72.
61. Grimminger, F., Weimann, G., Frey, R., Voswinckel, R., Thamm, M., Bölkow, D., Weissmann, N., Mück, W., Unger, S., Wensing, G., Schermuly, R.T., Ghofrani, H.A. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur. Respir. J. 33, 785-792.
62. Haddox M.K., Stephenson J.H., Moser M.E., Goldberg N.D. Oxidative-reductive modulation of guinea pig splenic cell guanylate cyclase activity. J. Biol. Chem. 1978, 253:3143-3152.
63. Handy D.E., Loscalzo J. Nitric oxide and posttranslational modification of the vascular proteome: S-nitrosation of reactive thiols. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1207-1214.
64. Hardman J.G., Sutherland E.W. Guanyl cyclase, an enzyme catalyzing the formation of guanosine 3',5'-monophosphate from guanosine trihosphate. J. Biol. Chem. 1969, 244:6363-6370.
65. Harteneck C., Wedel B., Koesling D., Malkewitz J., Bohme E., Schultz G. Molecular cloning and expression of a new alpha-subunit of soluble guanylyl cyclase. Interchangeability of the alpha-subunits of the enzyme. FEBS Lett 1991, 292:217-222.
66. Hassoun P.M., Filippov G., Fogel M., Donaldson C., Kayyali U.S., Shimoda L.A., Bloch K.D. Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. 2004, 30:908-913.
67. Hering K.W., Artz J.D., Pearson W.H., Marletta M.A. The design and synthesis of YC-1 analogues as probes for soluble guanylate cyclase. Bioorg. Med. Chem. Lett. 2006, 16:618-621.
68. Hibbs J.B., Taintor R.R., Vavrin Z., Rachlin E.M. Nitric Oxide: A cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 1988, 157:87-94.
69. Hobbs A.J. Soluble guanylate cyclase: an old therapeutic target re-visited. Br. J. Pharmacol. 2002, 136:637-640.
70. Hobbs A.J., Ignarro L.J. Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol 1996, 269:134-148.
71. Hobbs A.J., Moncada S. Inducible nitric oxide synthase and inflammation. Inducible Enzymes in the Inflammatory Response 1998, 31-54. Birkhauser Verlag, Basel, Switzerland. D.A. Willoughby, A. Tomlinson (Eds.).
72. Hobbs A.J., Moncada S. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vascul. Pharmacol. 2003, 40:149-154.
73. Hobbs A.J., Fukuto J.M., Ignarro L.J. Formation of free nitric oxide from l-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proc. Natl Acad. Sci. U S A 1994, 91:10992-10996.
74. Hobbs A.J., Higgs A., Moncada S. Inhibition of nitric oxide synthase as a potential therapeutic target. Annu. Rev. Pharmacol. Toxicol. 1999, 39:191-220.
75. Hoenicka M., Becker E.M., Apeler H., Sirichoke T., Schroder H., Gerzer R., Stasch J.P. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J. Mol. Med. 1999, 77:14-23.
76. Hoffmann L.S., Schmidt P.M., Keim Y., Schaefer S., Schmidt H.H., Stasch J.P. Distinct molecular requirements for activation of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br. J. Pharmacol. 2009, 157:781-795.
77. Hsieh G.C., O'Neill A.B., Moreland R.B., Sullivan J.P., Brioni J.D. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur. J. Pharmacol. 2003, 458:183-189.
78. Hussain A.S., Marks G.S., Brien J.F., Nakatsu K. The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-alpha]quinoxalin-1-one (ODQ) inhibits relaxation of rabbit aortic rings induced by carbon monoxide, nitric oxide, and glyceryl trinitrate. Can. J. Physiol Pharmacol. 1997, 75:1034-1037.
79. Ignarro L.J. Haem-dependent activation of cytosolic guanylate cyclase by nitric oxide: a widespread signal transduction mechanism. Biochem. Soc. Trans. 1992, 20:465-469.
80. Ignarro L.J., Byrns R.E., Buga G.M., Wood K.S. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 1987, 61:866-879.
81. Ignarro L.J., Lippton H., Edwards J.C., Baricos W.H., Hyman A.L., Kadowitz P.J., Gruetter C.A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 1981, 218:739-749.
82. Irvine J.C., Favaloro J.L., Kemp-Harper B.K. NO- activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 2003, 41:1301-1307.
83. Kalk P., Godes M., Relle K., Rothkegel C., Hucke A., Stasch J.P., Hocher B. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br. J. Pharmacol. 2006, 148:853-859.
84. Kalsi J.S., Rees R.W., Hobbs A.J., Royle M., Kell P.D., Ralph D.J., Moncada S., Cellek S. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J. Urol. 2003, 169:761-766.
85. Kamisaki Y., Saheki S., Nakane M., Palmieri J.A., Kuno T., Chang B.Y., Waldman S.A., Murad F. Soluble guanylate cyclase from rat lung exists as a heterodimer. J. Biol. Chem. 1986, 261:7236-7241.
86. Karow D.S., Pan D., Tran R., Pellicena P., Presley A., Mathies R.A., Marletta M.A. Spectroscopic characterization of the soluble guanylate cyclase-like heme domains from Vibrio cholerae and Thermoanaerobacter tengcongensis. Biochemistry 2004, 43:10203-10211.
87. Kharitonov V.G., Sharma V.S., Magde D., Koesling D. Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1. Biochemistry 1999, 38:10699-10706.
88. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994, 84:4226-4233.
89. Koesling D., Harteneck C., Humbert P., Bosserhoff A., Frank R., Schultz G., Bohme E. The primary structure of the larger subunit of soluble guanylyl cyclase from bovine lung. Homology between the two subunits of the enzyme. FEBS Lett. 1990, 266:128-132.
90. Koglin M., Behrends S. A functional domain of the alpha1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding. J. Biol. Chem. 2003, 278:12590-12597.
91. Koglin M., Stasch J.P., Behrends S. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. Biochem. Biophys. Res. Commun. 2002, 292:1057-1062.
92. Kollau A., Hofer A., Russwurm M., Koesling D., Keung W.M., Schmidt K., Brunner F., Mayer B. Contribution of aldehyde dehydrogenase to mitochondrial bioactivation of nitroglycerin: evidence for the activation of purified soluble guanylate cyclase through direct formation of nitric oxide. Biochem. J. 2005, 385:769-777.
93. Lamothe M., Chang F.J., Balashova N., Shirokov R., Beuve A. Functional characterization of nitric oxide and YC-1 activation of soluble guanylyl cyclase: structural implication for the YC-1 binding site?. Biochemistry 2004, 43:3039-3048.
94. Lapp H., Mitrovic V., Franz N., Heuer H., Buerke M., Wolfertz J., Muck W., Unger S., Wensing G., Frey R. BAY 58-2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile. BMC Pharmacol 2007, 7(Suppl. 1):S9.
95. Lapp H., Mitrovic V., Franz N., Heuer H., Buerke M., Wolfertz J., Mueck W., Unger S., Wensing G., Frey R. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009, 119:2781-2788.
96. Lawson D.M., Stevenson C.E., Andrew C.R., Eady R.R. Unprecedented proximal binding of nitric oxide to heme: implications for guanylate cyclase. EMBO J 2000, 19:5661-5671.
97. Liu Y.N., Pan S.L., Peng C.Y., Guh J.H., Huang D.M., Chang Y.L., Lin C.H., Pai H.C., Kuo S.C., Lee F.Y., Teng C.M. YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J. Pharmacol. Exp. Ther. 2006, 316:35-41.
98. Louis J.C., Revel M.O., Zwiller J. Activation of soluble guanylate cyclase through phosphorylation by protein kinase C in intact PC12 cells. Biochim. Biophys. Acta 1993, 1177:299-306.
99. Madhani M., Scotland R.S., MacAllister R.J., Hobbs A.J. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br. J. Pharmacol. 2003, 139:1289-1296.
100. Makino R., Obayashi E., Homma N., Shiro Y., Hori H. YC-1 facilitates release of the proximal His residue in the NO and CO complexes of soluble guanylate cyclase. J. Biol. Chem. 2003, 278:11130-11137.
101. Maron B.A., Zhang Y.Y., Handy D.E., Beuve A., Tang S.S., Loscalzo J., Leopold J.A. Aldosterone increases oxidant stress to impair guanylyl cyclase activity by cysteinyl thiol oxidation in vascular smooth muscle cells. J. Biol. Chem. 2009, 284:7665-7672.
102. Marro M.L., Peiro C., Panayiotou C.M., Baliga R.S., Meurer S., Schmidt H.H., Hobbs A.J. Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor. J. Biol. Chem. 2008, 283:20027-20036.
103. Martin W., Villani G.M., Jothianandan D., Furchgott R.F. Selective blockade of endothelium-dependent and glyceryl trinitrate- induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J. Pharmacol. Exp. Ther. 1985, 232:708-716.
104. Masuyama H., Tsuruda T., Kato J., Imamura T., Asada Y., Stasch J.P., Kitamura K., Eto T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 2006, 48:972-978.
105. Mayer B., Kleschyov A.L., Stessel H., Russwurm M., Münzel T., Koesling D., Schmidt K. Inactivation of soluble guanylate cyclase by stoichiometric S-nitrosation. Mol. Pharmacol. 2009, 75:886-891.
106. McLaughlin B.E., Chretien M.L., Choi C., Brien J.F., Nakatsu K., Marks G.S. Potentiation of carbon monoxide-induced relaxation of rat aorta by YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole]. Can. J. Physiol. Pharmacol. 2000, 78:343-349.
107. Melichar V.O., Behr-Roussel D., Zabel U., Uttenthal L.O., Rodrigo J., Rupin A., Verbeuren T.J., Kumar H.S.A., Schmidt H.H. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc. Natl. Acad Sci. U S A 2004, 101:16671-16676.
108. Meurer S., Pioch S., Pabst T., Opitz N., Schmidt P.M., Beckhaus T., Wagner K., Matt S., Gegenbauer K., Geschka S., Karas M., Stasch J.P., Schmidt H.H.H.W., Muller-Esterl W. Nitric Oxide-Independent Vasodilator Resources Heme-Oxidized Soluble Guanylate Cyclase From Proteasomal Degradation. Circ. Res. 2009, 105:33-41.
109. Miller L.N., Nakane M., Hsieh G.C., Chang R., Kolasa T., Moreland R.B., Brioni J.D. A-350619: a novel activator of soluble guanylyl cyclase. Life Sci. 2003, 72:1015-1025.
110. Mills R.M., LeJemtel T.H., Horton D.P., Liang C., Lang R., Silver M.A., Lui C., Chatterjee K. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J. Am. Coll. Cardiol. 1999, 34:155-162.
111. Mingone C.J., Gupte S.A., Ali N., Oeckler R.A., Wolin M.S. Thiol oxidation inhibits nitric oxide-mediated pulmonary artery relaxation and guanylate cyclase stimulation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L549-L557.
112. Mittendorf J., Weigand S., Alonso-Alija C., Bischoff E., Feurer A., Gerisch M., Kern A., Knorr A., Lang D., Muenter K., Radtke M., Schirok H., Schlemmer K.H., Stahl E., Straub A., Wunder F., Stasch J.P. Discovery of Riociguat (BAY63-2521): a potent oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem. Med. Chem. 2009, 4:853-865.
113. Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991, 43:109-142.
114. Motterlini R., Mann B.E., Johnson T.R., Clark J.E., Foresti R., Green C.J. Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Curr. Pharm. Des. 2003, 9:2525-2539.
115. Mulsch A., Bauersachs J., Schafer A., Stasch J.P., Kast R., Busse R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol. 1997, 120:681-689.
116. Mulligan C. Riociguat. Drugs of the Future 2009, 34:468-475.
117. Munzel T., Daiber A., Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ. Res. 2005, 97:618-628.
118. Munzel T., Kurz S., Heitzer T., Harrison D.G. New insights into mechanisms underlying nitrate tolerance. Am. J. Cardiol. 1996, 77:24C-30C.
119. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N. Engl. J. Med. 2006, 355:2003-2011.
120. Murthy K.S. Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem. J. 2001, 360:199-208.
121. Murthy K.S. Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase. J. Pharmacol. Exp. Ther. 2008, 325:183-189.
122. Nakane M., Kolasa T., Chang R., Miller L.N., Moreland R.B., Brioni J.D. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator. J. Pharmacol. Sci. 2006, 102:231-238.
123. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., Tannenbaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc. Natl. Acad Sci. U S A 1992, 89:3030-3034.
124. O'Reilly D.A., McLaughlin B.E., Marks G.S., Brien J.F., Nakatsu K. YC-1 enhances the responsiveness of tolerant vascular smooth muscle to glyceryl trinitrate. Can. J. Physiol. Pharmacol. 2001, 79:43-48.
125. Ohlstein E.H., Wood K.S., Ignarro L.J. Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch. Biochem. Biophys. 1982, 218:187-198.
126. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
127. Papapetropoulos A., Abou-Mohamed G., Marczin N., Murad F., Caldwell R.W., Catravas J.D. Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1 beta. Br. J. Pharmacol. 1996, 118:1359-1366.
128. Pellicena P., Karow D.S., Boon E.M., Marletta M.A., Kuriyan J. Crystal structure of an oxygen-binding heme domain related to soluble guanylate cyclases. Proc. Natl Acad. Sci. U S A 2004, 101:12854-12859.
129. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 1991, 288:481-487.
130. Rattan S., Al Haj R., De Godoy M.A. Mechanism of internal anal sphincter relaxation by CORM-1, authentic CO, and NANC nerve stimulation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G605-G611.
131. Richards A.M., Lainchbury J.G., Troughton R.W., Espiner E.A., Nicholls M.G. Clinical applications of B-type natriuretic peptides. Trends Endocrinol. Metab 2004, 15:170-174.
132. Ritter D., Taylor J.F., Hoffmann J.W., Carnaghi L., Giddings S.J., Zakeri H., Kwok P.Y. Alternative splicing for the alpha1 subunit of soluble guanylate cyclase. Biochem. J. 2000, 346(Pt 3):811-816.
133. Rothermund L., Friebe A., Paul M., Koesling D., Kreutz R. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br. J. Pharmacol. 2000, 130:205-208.
134. Rothkegel C., Schmidt P.M., Atkins D.J., Hoffmann L.S., Schmidt H.H., Schroder H., Stasch J.P. Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. Mol. Pharmacol. 2007, 72:1181-1190.
135. Rothkegel C., Schmidt P.M., Stoll F., Schroder H., Schmidt H.H., Stasch J.P. Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett. 2006, 580:4205-4213.
136. Roy B., Mo E., Vernon J., Garthwaite J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br. J. Pharmacol. 2008, 153:1495-1504.
137. Ruetten H., Zabel U., Linz W., Schmidt H.H. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ. Res. 1999, 85:534-541.
138. Russwurm M., Behrends S., Harteneck C., Koesling D. Functional properties of a naturally occurring isoform of soluble guanylyl cyclase. Biochem. J. 1998, 335(Pt 1):125-130.
139. Russwurm M., Mergia E., Mullershausen F., Koesling D. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J. Biol. Chem. 2002, 277:24883-24888.
140. Russwurm M., Wittau N., Koesling D. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J. Biol. Chem. 2001, 276:44647-44652.
141. Sackner-Bernstein J.D., Kowalski M., Fox M., Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905.
142. Schermuly R.T., Stasch J.P., Pullamsetti S.S., Middendorff R., Muller D., Schluter K.D., Dingendorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., Ghofrani H.A., Grimminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 2008, 32:881-891.
143. Schindler U., Strobel H., Schonafinger K., Linz W., Lohn M., Martorana P.A., Rutten H., Schindler P.W., Busch A.E., Sohn M., Topfer A., Pistorius A., Jannek C., Mulsch A. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol. Pharmacol. 2006, 69:1260-1268.
144. Schmidt H.H., Hofmann H., Schindler U., Shutenko Z.S., Cunningham D.D., Feelisch M. No. NO from NO synthase. Proc. Natl Acad. Sci. U S A 1996, 93:14492-14497.
145. Schmidt H.H., Lohmann S.M., Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim. Biophys. Acta 1993, 1178:153-175.
146. Schmidt H.H., Schmidt P.M., Stasch J.P. NO- and Haem-Independent Soluble Guanylate Cyclase Activators. Handb. Exp. Pharmacol. 2009, 309-339.
147. Schmidt P., Schramm M., Schroder H., Stasch J.P. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur. J. Pharmacol. 2003, 468:167-174.
148. Schmidt P.M., Rothkegel C., Wunder F., Schroder H., Stasch J.P. Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. Eur. J. Pharmacol. 2005, 513:67-74.
149. Schmidt P.M., Schramm M., Schroder H., Wunder F., Stasch J.P. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J. Biol. Chem. 2004, 279:3025-3032.
150. Selwood D.L., Brummell D.G., Budworth J., Burtin G.E., Campbell R.O., Chana S.S., Charles I.G., Fernandez P.A., Glen R.C., Goggin M.C., Hobbs A.J., Kling M.R., Liu Q., Madge D.J., Meillerais S., Powell K.L., Reynolds K., Spacey G.D., Stables J.N., Tatlock M.A., Wheeler K.A., Wishart G., Woo C.K. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J. Med. Chem. 2001, 44:78-93.
151. Sharina I.G., Martin E., Thomas A., Uray K.L., Murad F. CCAAT-binding factor regulates expression of the beta1 subunit of soluble guanylyl cyclase gene in the BE2 human neuroblastoma cell line. Proc. Natl Acad. Sci. U S A 2003, 100:11523-11528.
152. Sharma V.S., Magde D., Kharitonov V.G., Koesling D. Soluble guanylate cyclase: effect of YC-1 on ligation kinetics with carbon monoxide. Biochem. Biophys. Res. Commun. 1999, 254:188-191.
153. Shiga T., Suzuki N. Amphipathic alpha-helix mediates the heterodimerization of soluble guanylyl cyclase. Zool. Sci. 2005, 22:735-742.
154. Shimouchi A., Janssens S.P., Bloch D.B., Zapol W.M., Bloch K.D. cAMP regulates soluble guanylate cyclase beta 1-subunit gene expression in RFL-6 rat fetal lung fibroblasts. Am. J. Physiol. 1993, 265:L456-L461.
155. Stasch J.P., Hobbs A.J. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 2009, 91:277-308.
156. Stasch J.P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol. 2002, 135:333-343.
157. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410:212-215.
158. Stasch J.P., Dembowsky K., Perzborn E., Stahl E., Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol. 2002, 135:344-355.
159. Stasch J.P., Schmidt P., Alonso-Alija C., Apeler H., Dembowsky K., Haerter M., Heil M., Minuth T., Perzborn E., Pleiss U., Schramm M., Schroeder W., Schroder H., Stahl E., Steinke W., Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol. 2002, 136:773-783.
160. Stasch J.P., Schmidt P.M., Nedvetsky P.I., Nedvetskaya T.Y., AK H.S., Meurer S., Deile M., Taye A., Knorr A., Lapp H., Müller H., Turgay Y., Rothkegel C., Tersteegen A., Kemp-Harper B., Müller-Esterl W., Schmidt H.H. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 2006, 116:2552-2561.
161. Stone J.R., Marletta M.A. The ferrous heme of soluble guanylate cyclase: formation of hexacoordinate complexes with carbon monoxide and nitrosomethane. Biochemistry 1995, 34:16397-16403.
162. Stone J.R., Marletta M.A. Synergistic activation of soluble guanylate cyclase by YC-1 and carbon monoxide: implications for the role of cleavage of the iron-histidine bond during activation by nitric oxide. Chem. Biol. 1998, 5:255-261.
163. Stone J.R., Sands R.H., Dunham W.R., Marletta M.A. Electron paramagnetic resonance spectral evidence for the formation of a pentacoordinate nitrosyl-heme complex on soluble guanylate cyclase. Biochem. Biophys. Res. Commun. 1995, 207:572-577.
164. Stone J.R., Sands R.H., Dunham W.R., Marletta M.A. Spectral and ligand-binding properties of an unusual hemoprotein, the ferric form of soluble guanylate cyclase. Biochemistry 1996, 35:3258-3262.
165. Straub A., Benet-Buckholz J., Fröde R., Kern A., Kohlsdorfer C., Schmitt P., Schwarz T., Siefert H.M., Stasch J.P. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. 2002, 10:1711-1717.
166. Straub A., Stasch J.P., Alonso-Alija C., Benet-Buchholz J., Ducke B., Feurer A., Furstner C. NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett. 2001, 11:781-784.
167. Sydow K., Daiber A., Oelze M., Chen Z., August M., Wendt M., Ullrich V., Mulsch A., Schulz E., Keaney J.F., Stamler J.S., Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J. Clin. Invest. 2004, 113:482-489.
168. Teixeira C.E., Priviero F.B., Claudino M.A., Baracat J.S., De N.G., Webb R.C., Antunes E. Stimulation of soluble guanylyl cyclase by BAY 41-2272 relaxes anococcygeus muscle: interaction with nitric oxide. Eur. J. Pharmacol. 2006, 530:157-165.
169. Teixeira C.E., Priviero F.B., Webb R.C. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyri mi din-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole]. J. Pharmacol. Exp. Ther. 2006, 317:258-266.
170. Traylor T.G., Sharma V.S. Why NO?. Biochemistry 1992, 31:2847-2849.
171. Tulis D.A., Durante W., Peyton K.J., Chapman G.B., Evans A.J., Schafer A.I. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. Biochem. Biophys. Res. Commun. 2000, 279:646-652.
172. Venema R.C., Venema V.J., Ju H., Harris M.B., Snead C., Jilling T., Dimitropoulou C., Maragoudakis M.E., Catravas J.D. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H669-H678.
173. Wagner C., Russwurm M., Jager R., Friebe A., Koesling D. Dimerization of nitric oxide-sensitive guanylyl cyclase requires the alpha 1N terminus. J. Biol. Chem. 2005, 280:17687-17693.
174. Wang J.P., Chang L.C., Huang L.J., Kuo S.C. Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. Biochem. Pharmacol. 2001, 62:679-684.
175. Wedel B., Humbert P., Harteneck C., Foerster J., Malkewitz J., Bohme E., Schultz G., Koesling D. Mutation of His-105 in the beta 1 subunit yields a nitric oxide- insensitive form of soluble guanylyl cyclase. Proc. Natl. Acad. Sci. U S A 1994, 91:2592-2596.
176. Weimann J., Ullrich R., Hromi J., Fujino Y., Clark M.W., Bloch K.D., Zapol W.M. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000, 92:1702-1712.
177. Wharton J., Strange J.W., Moller G.M., Growcott E.J., Ren X., Franklyn A.P., Phillips S.C., Wilkins M.R. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. 2005, 172:105-113.
178. White A.A., Crawford K.M., Patt C.S., Lad P.J. Activation of soluble guanylate cyclase from rat lung by incubation or by hydrogen peroxide. J. Biol. Chem. 1976, 251:7304-7312.
179. Wilson E.M., Chinkers M. Identification of sequences mediating guanylyl cyclase dimerization. Biochemistry 1995, 34:4696-4701.
180. Wolin M.S. Loss of vascular regulation by soluble guanylate cyclase is emerging as a key target of the hypertensive disease process. Hypertension 2005, 45:1068-1069.
181. Wolin M.S., Wood K.S., Ignarro L.J. Guanylate cyclase from bovine lung. A kinetic analysis of the regulation of the purified soluble enzyme by protoporphyrin IX, heme, and nitrosyl-heme. J. Biol. Chem. 1982, 257:13312-13320.
182. Wong P.S., Hyun J., Fukuto J.M., Shirota F.N., DeMaster E.G., Shoeman D.W., Nagasawa H.T. Reaction between S-nitrosothiols and thiols: generation of nitroxyl (HNO) and subsequent chemistry. Biochemistry 1998, 37:5362-5371.
183. Wu C.H., Chang W.C., Chang G.Y., Kuo S.C., Teng C.M. The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. J. Pharmacol. Sci. 2004, 94:252-260.
184. Wu X.B., Brune B., Von Appen F., Ullrich V. Reversible activation of soluble guanylate cyclase by oxidizing agents. Arch. Biochem. Biophys. 1992, 294:75-82.
185. Wunder F., Stasch J.P., Hutter J., onso-Alija C., Huser J., Lohrmann E. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal. Biochem. 2005, 339:104-112.
186. Yuen P.S., Potter L.R., Garbers D.L. A new form of guanylyl cyclase is preferentially expressed in rat kidney. Biochemistry 1990, 29:10872-10878.
187. Zabel U., Hausler C., Weeger M., Schmidt H.H. Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. J. Biol. Chem. 1999, 274:18149-18152.
188. Zabel U., Kleinschnitz C., Oh P., Nedvetsky P., Smolenski A., Muller H., Kronich P., Kugler P., Walter U., Schnitzer J.E., Schmidt H.H. Calcium-dependent membrane association sensitizes soluble guanylyl cyclase to nitric oxide. Nat. Cell Biol. 2002, 4:307-311.
189. Zanfolin M., Faro R., Araujo E.G., Guaraldo A.M., Antunes E., De N.G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J. Cardiovasc. Pharmacol. 2006, 47:391-395.
190. Zhao Y., Brandish P.E., DiValentin M., Schelvis J.P., Babcock G.T., Marletta M.A. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 2000, 39:10848-10854.
191. Zhou Z., Gross S., Roussos C., Meurer S., Muller-Esterl W., Papapetropoulos A. Structural and functional characterization of the dimerization region of soluble guanylyl cyclase. J. Biol. Chem. 2004, 279:24935-24943.
192. Zhou Z., Pyriochou A., Kotanidou A., Dalkas G., van E.M., Spyroulias G., Roussos C., Papapetropoulos A. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1763-H1771.
193. Zwiller J., Revel M.O., Basset P. Evidence for phosphorylation of rat brain guanylate cyclase by cyclic AMP-dependent protein kinase. Biochem. Biophys. Res. Commun. 1981, 101:1381-1387.
194. Zwiller J., Revel M.O., Malviya A.N. Protein kinase C catalyzes phosphorylation of guanylate cyclase in vitro. J. Biol. Chem. 1985, 260:1350-1353.